The EMA's CHMP has taken a negative view on its decision to recommend approval of Exondys 51 (eteplirsen) injection, from...
The FDA has approved Exondys 51 (eteplirsen) injection, from Sarepta Therapeutics, the first drug approved to treat patients with Duchenne...
Sarepta Therapeutics has announced that the FDA Peripheral and Central Nervous System Advisory Committee (PCNSC) met to review the new...
The FDA has rescheduled its advisory committee review of Exondys (eteplirsen), from Sarepta, to 25 April 2016. Comment: Sarepta has...
Sarepta Therapeutics and Summit Therapeutics plc announced that they have entered into an exclusive license and collaboration agreement granting Sarepta...
CV Disease in Special Populations
Cardiac Issues in Prostate Cancer management